Imlifidase
Imlifidase is an IgG-cleaving enzyme (IdeS) that removes circulating IgG within hours. Hansa Biopharma evaluated it for rapidly clearing pathogenic autoantibodies in anti-GBM disease (the GOOD-IDES-02 study).
Also known as: IDEFIRIX, IdeS
Imlifidase forecasting benchmarks
1 benchmarkMechanism & molecular targets
Indications studied
Developed by
About Imlifidase
What is Imlifidase?
Imlifidase is an IgG-cleaving enzyme (IdeS) that removes circulating IgG within hours. Hansa Biopharma evaluated it for rapidly clearing pathogenic autoantibodies in anti-GBM disease (the GOOD-IDES-02 study). It is a igg-cleaving cysteine protease (ides) developed by Hansa Biopharma.
What does Imlifidase target?
Imlifidase acts on Pathogenic IgG (IdeS cleavage).
How well do AI models predict Imlifidase trial outcomes?
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.